- Home
- REGN vs CTVA Comparison
REGN vs CTVA Comparison
Compare REGN & CTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- CTVA
- Stock Information
- Founded
- REGN 1988
- CTVA 2018
- Country
- REGN United States
- CTVA United States
- Employees
- REGN N/A
- CTVA N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- CTVA Farming/Seeds/Milling
- Sector
- REGN Health Care
- CTVA Consumer Staples
- Exchange
- REGN Nasdaq
- CTVA Nasdaq
- Market Cap
- REGN 59.5B
- CTVA 48.7B
- IPO Year
- REGN 1991
- CTVA N/A
- Fundamental
- Price
- REGN $560.00
- CTVA $74.32
- Analyst Decision
- REGN Buy
- CTVA Strong Buy
- Analyst Count
- REGN 23
- CTVA 14
- Target Price
- REGN $794.83
- CTVA $80.43
- AVG Volume (30 Days)
- REGN 972.9K
- CTVA 3.7M
- Earning Date
- REGN 10-30-2025
- CTVA 11-05-2025
- Dividend Yield
- REGN 0.63%
- CTVA 0.97%
- EPS Growth
- REGN 5.03
- CTVA 60.76
- EPS
- REGN 39.67
- CTVA 2.03
- Revenue
- REGN $14,214,200,000.00
- CTVA $17,177,000,000.00
- Revenue This Year
- REGN N/A
- CTVA $6.25
- Revenue Next Year
- REGN $4.86
- CTVA $3.44
- P/E Ratio
- REGN $14.12
- CTVA $34.83
- Revenue Growth
- REGN 5.38
- CTVA 1.63
- 52 Week Low
- REGN $476.49
- CTVA $53.40
- 52 Week High
- REGN $1,170.58
- CTVA $77.41
- Technical
- Relative Strength Index (RSI)
- REGN 46.27
- CTVA 57.93
- Support Level
- REGN $552.98
- CTVA $71.56
- Resistance Level
- REGN $570.76
- CTVA $73.66
- Average True Range (ATR)
- REGN 15.16
- CTVA 1.44
- MACD
- REGN -2.91
- CTVA 0.00
- Stochastic Oscillator
- REGN 16.26
- CTVA 64.82
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About CTVA Corteva Inc.
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.